Canadian consensus recommendations for the optimal use of enfuvirtide in HIV/AIDS patients

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 17, Issue 3, 2006, Pages 155-163

  Rachlis, Anita ^a   Angel, Jonathan ^b   Harris, Marianne ^c   Lalonde, Richard ^d   Smaill, Fiona ^e   Tremblay, Cecile ^f   Tsoukas, Chris ^d   Walmsley, Sharon ^g  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

AIDS; HIV; Recommendations; Treatment

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR; ENFUVIRTIDE; RITONAVIR; TIPRANAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS PATIENT; ANTIBIOTIC RESISTANCE; BODY FAT DISTRIBUTION; CANADA; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MONITORING; ERYTHEMA; EVIDENCE BASED PRACTICE; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE ABSCESS; INJECTION SITE CELLULITIS; INJECTION SITE REACTION; MEDICAL SPECIALIST; MULTIDRUG RESISTANCE; NAUSEA; PATIENT CARE; PATIENT EDUCATION; PATIENT SELECTION; PNEUMONIA; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; TREATMENT PLANNING; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

EID: 33746904705     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/402409     Document Type: Review

References (74)

1. Clotet B, Raffi F, Cooper D, et al. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: Consensus recommendations. AIDS 2004;18:1137-46.
2. Mocroft A, Ledergerber B, Katlama C, et al; EuroSIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 2003;362:22-9.
3. Walensky R, Paltiel A, Losina E, et al. Two million years of life saved: The survival benefits of AIDS therapy in the United States. In: 12th Conference on Retroviruses and Opportunistic Infections, February 22 to 25, 2005, Boston, Massachusetts (abstract 143LB).
4. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, 〈www.aidsinfo.nih.gov/guidelines〉 (Version current at June 5, 2006).
5. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA Panel. JAMA 2004;292:251-65.
6. Rinehart A, Lecocq P, Pattery T, Wasikowsi B, Bacheler L. Evolution in the diversity of HIV-1-resistance mutation patterns in >128,000 clinical samples received for resistance analysis from 1998 to 2004. In: 12th Conference on Retroviruses and Opportunistic Infections, February 22 to 25, 2005, Boston, Massachusetts (abstract 684).
7. Lohse N, Obel N, Kronborg G, et al. Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals. AIDS 2005;19:815-22.
8. Lampe F, Gatell J, Staszewski S, et al. Trends over time in initial virological failure of first HAART: 1996 to 2002. A joint cohort analysis of 4143 subjects. In: 12th Conference on Retroviruses and Opportunistic Infections, February 22 to 25, 2005, Boston, Massachusetts (abst 593).
9. Bartlett J, Fath M, DeMasi R, et al. An updated meta-analysis of triple combination therapy in antiretroviral-naive HIV-infected adults. In: 12th Conference on Retroviruses and Opportunistic Infections, February 22 to 25, 2005, Boston, Massachusetts (abst 586).
10. Hogg RS, Bangsberg D, Alexander C, et al. Drug resistance is associated with an increased risk of death in patients first starting HAART. In: 12th Conference on Retroviruses and Opportunistic Infections, February 22 to 25, 2005, Boston. Massachusetts (abst 712).
11. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV N Engl J Med 2002;347:385-94.
12. Markowitz M, Mohri H, Mehandru S, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: A case report. Lancet 2005;365:1031-8.
13. Vandamme AM, Sonnerborg A, Ait-Khaled M, et al. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004;9:829-48.
14. Harrigan PR, Wynhoven B, Brumme ZL, et al. HIV-1 drug resistance: Degree of underestimation by a cross-sectional versus a longitudinal testing approach. J Infect Dis 2005;191:1325-30.
15. Loutfy MR, Walmsley SL, Mullin CM, Perez G, Neaton JD; Terry Beirn Community Programs for Clinical Research on AIDS; Canada HIV Trials Network. CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy. J Infect Dis 2005;192:1407-11.
16. Montaner JS, Harris M, Harrigan R, Hogg R, Wood E. A compromise strategy for patients with multiple drug failure. AIDS 2001;15:2470.
17. Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D. Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 2004;3:215-25.
18. Product monograph, Hoffmann-La Roche Limited. FUZEON (enfuvirtide) for injection single-use vials: 108 mg/vial. Antiviral Agent (HIV-1 Fusion Inhibitor).
19. Zhang X, Lalezari JP, Badley AD, et al. Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther 2004;75:558-68.
20. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85. (Erratum in 2003;349:1100).
21. Lazzarin A, Clotet B, Cooper D, et al; TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-95.
22. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005;40:404-12.
23. Arasteh K, Lazzarin A, Clotet B, et al. TORO: 96 week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen. Conference Abstract number MoOrB1058. Presented at the XV International AIDS Conference, July 11 to 16, 2004, Bangkok, Thailand.
24. Cohen C, DeMasi R, Greenberg M, et al. Selection of non-enfuvirtide (ENF) vs. ENF-containing regimens leads to higher failure rates and loss of future antiretroviral (ARV) treatment options (poster H-580). Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30 to November 2, 2004, Washington, DC.
25. Hicks C. RESIST-1: A phase 3, randomized, controlled, open label multicenter trial comprising tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24 week data. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30 to November 2, 2004, Washington, CC. (abst H-1137a)
26. Cahn P, Hicks C. RESIST-1 (R-1) and RESIST-2 (R-2) 48-week meta-analyses demonstrate superiority of protease inhibitor (PI) tipranavir+ritonavir (TPV/R) over an optimized comparator PI (CPR/R) regimen in antiretroviral (ARV) experienced patients. In: Program and abstracts of the 10th European AIDS Conference, November 17 to 20, 2005, Dublin, Ireland, (abst LBPS3/8)
27. Katlama C, Carvalho MT, Cooper D, et al. TMC114/r outperforms investigator-selected PI(s) in 3-class-experienced patients: Week 24 primary efficacy analysis of POWER 1 (TMC114-C213). Presented at the 3rd IAS Conference on HIV Pathogenesis and Treatment, July 24 to 27, 2005, Rio de Janeiro, Brazil, (poster WeOaLB0102)
28. Wilkin T, Haubrich R, Steinhart CR, et al. TMC114/r superior to standard of care in 3-class-experienced patients: 24-wks primary analysis of the POWER 2 study (C202). In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16 to 19, 2005, Washington, DC. (abst H-413)
29. Trottier B, Walmsley S, Reynes J, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr 2005;40:413-21.
30. Cooper DA, Reiss P, Henry K, et al. The effects of enfuvirtide therapy on body composition and serum lipids through 48 weeks in the TORO trials. Presented at the 11th Conference on Retroviruses and Opportunistic Infections, February 8 to 12, 2004, San Francisco, California, (poster number 715)
31. Walmsley S, Henry K, Katlama C, et al. Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide. J Infect Dis 2003;188:1827-33.
32. Sista PR, Melby T, Greenberg ML, et al. Subgroup analysis of baseline susceptibility and early virological response to enfuvirtide in the combined TORO studies. Antivir Ther 2003;8:S60.
33. Sista PR, Melby T, Davison D, et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004;18:1787-94.
34. Su C, Heilek-Snyder C, Ravindran P, et al. Substitutions within HIV gp41 amino acids 36-45 are identified as the primary determinants for loss of in vitro susceptibility to enfuvirtide: Results of data mining analyses of genotypic changes in gp41 in TORO 1 and TORO 2 that associate with changes in phenotypic susceptibility to enfuvirtide. Presented at the XIII International HIV Drug Resistance Workshop, June 8 to 12, 2004, Canary Islands, Spain, (poster number 162)
35. Loutfy M, Montaner J, Raboud J, et al. Genotypic resistance assay for entire gp-41 sequence with identification of gp-41 polymorphisms in enfuvirtide-naïve patients and new gp-41 mutations in patients failing enfuvirtide. In: Program and abstracts of the XV International AIDS Conference, July 11 to 16, 2004, Bangkok, Thailand, (abst WeOrB1292)
36. Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004;54:333-40.
37. Deeks S, Lu J, Hoh R, et al. Interruption of enfuvirtide in patients with enfuvirtide resistance. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, February 22 to 25, 2005, Boston, Massachusetts, (abst 680)
38. Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 2004;78:4628-37.
39. Cooper D, Hicks C, Cahn P, et al. 24-Week RESIST Study Analyses: The efficacy of tipranavir/ritonavir is superior to lopinavir/ritonavir, and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, February 22 to 25, 2005, Boston, Massachusetts, (abst 560)
40. Valdez H, McCallister S, Kohlbrenner V, et al. Tipranavir/ritonavir (TPV/r) 500 mg/200 mg BID drives week 24 viral load (VL) below 400 copies/mL when combined with a second active drug (T-20) in protease inhibitor experienced HIV+ patients. In: Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment, July 24 to 27, 2005, Rio de Janeiro, Brazil, (abst WeOa0205)
41. Montaner J, Guimaraes D, Chung J, Gafoor Z, Salgo M, DeMasi R. Prognostic staging of extensively pretreated patients with advanced HIV-1 disease. HIV Clin Trials 2005;6:281-90.
42. Walmsley S, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in subgroups of patients through 48 weeks of therapy in the TORO trials. Presented at the 9th European AIDS Conference, October 25 to 29, 2003, Warsaw, Poland, (poster number 7.3/15)
43. Ruiz L, Romeu J, Martinez-Picado J, et al. Selection of drug-resistance mutations in chronic HIV-infected patients during therapy Interruptions guided by CD4+ T-cell counts and viral load levels: The Tibet Study. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, February 22 to 25, 2005, Boston, Massachusetts, (abst 679)
44. Hatano H, Hunt P, Weidler J, et al. Rate of viral evolution and risk of losing future drug options in heavily pre-treated patients remaining on a stable partially suppressive regimen. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections, February 5 to 6, 2006, Denver, Colorado, (abst 615)
45. Church JA, Hughes M, Chen J, et al; Pediatric AIDS Clinical Trials Group P1005 Study Team. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 2004;23:713-18.
46. Bellibas SE, Siddique Z, Dorr A, et al; T20-310/NV16056 Study Group. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. Pediatr Infect Dis J 2004;23:1137-41.
47. Bourgarit A, Lascoux C, Palmer P, et al. First-line use of enfuvirtide-containing HAART regimen with dramatic clinical and immunological improvement in three cases. AIDS 2006;20:471-3.
48. Miralles GD, Dolker M, Thommes J, et al. Effect of treatment interruptions on estimation of baseline (BL) antiretroviral (ARV) susceptibility and subsequent virological response in treatment-experienced patients. Presented at the 7th International Congress on Drug Therapy in HIV Infection, November 14 to 18, 2004, Glasgow, United Kingdom, (poster number P17)
49. Beatty G, Lu J, Hunt P, et al. Randomized pilot study of immediate enfuvirtide-based therapy vs. a treatment interruption followed by enfuvirtide-based therapy in highly treatment-experienced patients. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, February 22 to 25, 2005, Boston, Massachusetts, (abstract 581)
50. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000;14:F83-93.
51. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet 1999;353:2195-9. (Erratum in 1999;354:1128).
52. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: The Havana trial. AIDS 2002;16:209-18.
53. Hirschel B. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy, by Cohen et al. AIDS 2003;17(Suppl 4):S114-6.
54. Wegner SA, Wallace MR, Aronson NE, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: Results of the clinical efficacy of resistance testing trial. Clin Infect Dis 2004;38:723-30.
55. Perez-Elias MJ, Garcia-Arota I, Munoz V, et al. Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: A prospective, randomized study. Antivir Ther 2003;8:577-84.
56. De Meyer S, Hill A, De Baere I, et al. Effect of baseline susceptibility and on-treatment mutations on TMC114 and control PI efficacy: Preliminary analysis of data from Pi-experienced patients from POWER 1 and POWER 2. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections, February 5 to 6, 2006, Denver, Colorado, (abst 157)
57. Henry K, Lalezari M, O'Hearn M, et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen alone in patients with prior experience or resistance to each of the three classes of approved antiretrovirals (ARVs) in North America and Brazil. In: Program and abstracts of the XIV International AIDS Conference, July 7 to 12, 2002, Barcelona, Spain, (abst LbOr19B)
58. Schapiro J, Cahn P, Trottier B, et al. Effect of baseline genotype on response to tipranavir/ritonavir (TPV/r) compared with standard-of-care comparator (CPI/r) in treatment-experienced patients: The Phase 3 RESIST-1 and -2 Trials. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, February 22 to 25, 2005, Boston, Massachusetts, (abst 104)
59. Bonora S, Gonzalez de Requena D, Castagna A, et al. Pharmacokinetic and pharmacodynamic determinants of virological response to enfuvirtide-based regimens. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, February 22 to 25, 2005, Boston, Massachusetts, (abst 643)
60. Zhang X, Buss N, Salgo M, et al. Enfuvirtide pharmacokinetic- pharmacodynamic (PK-PD) relationship. Presented at the 9th European AIDS Conference, October 25 to 29, 2003, Warsaw, Poland, (poster number 4.1/4)
61. Raffi F, Katlama C, Saag M, et al. Week-12 response to therapy as a predictor of week 24, 48 and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus optimized regimen only (TORO) trials. Clin Infect Dis 2006;42:870-7.
62. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001;344:472-80.
63. Morse C, Maldarelli F, Dewar R, et al. Limited evolution of drug resistance in HIV-1 infected patients with persistent low-level viremia on a stable antiretroviral regimen for greater than one year. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, February 22 to 25, 2005, Boston, Massachusetts, (poster number 678)
64. Menzo S, Castagna A, Monachetti A, et al. Resistance and replicative capacity of HIV-1 strains selected in vivo by long term enfuvirtide treatment. New Microbiol 2004;27(2 Suppl 1):51-61.
65. Bonjoch A, Puig J, Miranda C, et al. Discontinuation of T-20 in HIV-infected patients on long lasting viral suppression. In: Program and abstracts of the 45th Interscience Conference of Antimicrobial Agents and Chemotherapy, December 16 to 19, 2005, Washington, DC. (abst H-527)
66. Harris M, Larsen G, Valyi M, et al. Early experience in the use of the Bioject Needle-free Injection System (Biojector) for the Delivery of T20 (enfuvirtide) in treatment-experienced patients. Presented at the HIV DART 2004, December 12 to 16, 2004, Montego Bay, Jamaica, (poster number 063)
67. Gallant JE, Mackowiak JI, Dusek AC, Falcon RW, DeMasi R. Change in injection attitudes and patient-reported outcomes among patients with enfuvirtide (ENF) experience. In: Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment, July 24 to 27, 2005, Rio de Janeiro, Brazil. (abst WePe12.9C13)
68. Harris M, Joy R, Larsen G, et al. Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector). AIDS 2006;20:719-23.
69. True AS, Luo R, DeMasi R, Falcon R. An evaluation of HIV patient quality of life and tolerability after administration of enfuvirtide-based HAART using a smaller needle in a community practice setting. In: Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment, July 24 to 27, 2005, Rio de Janeiro, Brazil, (abst WePe6.3C09)
70. Shahar E, Moar C, Pollack S. Successful desensitization of enfuvirtide-induced skin hypersensitivity reaction. AIDS 2005;19;451-2.
71. Centers for Disease Control and Prevention. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis, 〈www.cdc.gov/mmwr/preview/ mmwrhtml/rr5409al.htm〉 (Version current at May 26, 2006).
72. Varsalone D, Swartz K, Mohammed D. An enfuvirtide empowerment program: Do Not Enter. Presented at the 7th International Congress on Drug Therapy in HIV Infection, November 14 to 18, 2004, Glasgow, United Kingdom, (poster number P210)
73. Goodly J, DeMasi R, Khoo K, Mazikewich A, Thommes J. Optimal adherence to enfuvirtide achieved in the US Early Access Program. Presented at the 7th International Congress on Drug Therapy in HIV Infection, November 14 to 18, 2004, Glasgow, United Kingdom, (poster number P130)
74. Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. Clin Infect Dis 1994;18:421.